David Camidge
SWOG Cancer Research Network · University of Colorado, Denver
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Camidge as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02134912 · S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibSWOG Cancer Research Network · terminated · Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT00778167 · Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNational Cancer Institute (NCI) · completed · Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- A randomized phase II study of erlotinib with or without the anti-IGF-1R monoclonR21CA135595 · NCI · UNIVERSITY OF COLORADO DENVER · fiscal years 2008 to 2009 · $348,354 awarded in 2009Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026Named on NCT02134912
- Southwest Oncology Group Treatment GrantU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 2013Named on NCT02134912
- Genomics Shared ResourceP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · fiscal years 2012 to 2026Named on NCT00778167
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:37 UTC. The ranking covers the 200 most relevant of 87 PubMed records, and a shared surname and initials can bring in a namesake. All 87 on PubMed
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med · 20103,653 citationsRCR 86.4
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.N Engl J Med · 20132,837 citationsRCR 78.7
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 20172,061 citationsRCR 67.4
- Crizotinib in ROS1-rearranged non-small-cell lung cancer.N Engl J Med · 20141,567 citationsRCR 42.3
- Ceritinib in ALK-rearranged non-small-cell lung cancer.N Engl J Med · 20141,179 citationsRCR 32.9
- 1,090 citationsRCR 44.6
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol · 20121,021 citationsRCR 26.5
- 936 citationsRCR 31.8
- Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2018824 citationsRCR 27.7
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.Lancet Oncol · 2018642 citationsRCR 21.1